248 related articles for article (PubMed ID: 32379724)
1. Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease.
Wooddell CI; Blomenkamp K; Peterson RM; Subbotin VM; Schwabe C; Hamilton J; Chu Q; Christianson DR; Hegge JO; Kolbe J; Hamilton HL; Branca-Afrazi MF; Given BD; Lewis DL; Gane E; Kanner SB; Teckman JH
JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32379724
[TBL] [Abstract][Full Text] [Related]
2. Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.
Turner AM; Stolk J; Bals R; Lickliter JD; Hamilton J; Christianson DR; Given BD; Burdon JG; Loomba R; Stoller JK; Teckman JH
J Hepatol; 2018 Aug; 69(2):378-384. PubMed ID: 29572094
[TBL] [Abstract][Full Text] [Related]
3. RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease.
Strnad P; San Martin J
Expert Opin Investig Drugs; 2023; 32(7):571-581. PubMed ID: 37470509
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice.
Shen S; Sanchez ME; Blomenkamp K; Corcoran EM; Marco E; Yudkoff CJ; Jiang H; Teckman JH; Bumcrot D; Albright CF
Hum Gene Ther; 2018 Aug; 29(8):861-873. PubMed ID: 29641323
[TBL] [Abstract][Full Text] [Related]
5. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency.
Borel F; Tang Q; Gernoux G; Greer C; Wang Z; Barzel A; Kay MA; Shultz LD; Greiner DL; Flotte TR; Brehm MA; Mueller C
Mol Ther; 2017 Nov; 25(11):2477-2489. PubMed ID: 29032169
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human α1-antitrypsin.
Baligar P; Kochat V; Arindkar SK; Equbal Z; Mukherjee S; Patel S; Nagarajan P; Mohanty S; Teckman JH; Mukhopadhyay A
Hepatology; 2017 Apr; 65(4):1319-1335. PubMed ID: 28056498
[TBL] [Abstract][Full Text] [Related]
7. Fazirsiran for Liver Disease Associated with Alpha
Strnad P; Mandorfer M; Choudhury G; Griffiths W; Trautwein C; Loomba R; Schluep T; Chang T; Yi M; Given BD; Hamilton JC; San Martin J; Teckman JH
N Engl J Med; 2022 Aug; 387(6):514-524. PubMed ID: 35748699
[TBL] [Abstract][Full Text] [Related]
8. Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy.
Teckman JH
COPD; 2013 Mar; 10 Suppl 1():35-43. PubMed ID: 23527737
[TBL] [Abstract][Full Text] [Related]
9. The unfolded protein response to PI*Z alpha-1 antitrypsin in human hepatocellular and murine models.
Lu Y; Wang LR; Lee J; Mohammad NS; Aranyos AM; Gould C; Khodayari N; Oshins RA; Moneypenny CG; Brantly ML
Hepatol Commun; 2022 Sep; 6(9):2354-2367. PubMed ID: 35621045
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte proteomes reveal the role of protein disulfide isomerase 4 in alpha 1-antitrypsin deficiency.
Karatas E; Raymond AA; Leon C; Dupuy JW; Di-Tommaso S; Senant N; Collardeau-Frachon S; Ruiz M; Lachaux A; Saltel F; Bouchecareilh M
JHEP Rep; 2021 Aug; 3(4):100297. PubMed ID: 34151245
[TBL] [Abstract][Full Text] [Related]
11. Heteropolymerization of α-1-antitrypsin mutants in cell models mimicking heterozygosity.
Laffranchi M; Berardelli R; Ronzoni R; Lomas DA; Fra A
Hum Mol Genet; 2018 May; 27(10):1785-1793. PubMed ID: 29538751
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice.
Guo S; Booten SL; Aghajan M; Hung G; Zhao C; Blomenkamp K; Gattis D; Watt A; Freier SM; Teckman JH; McCaleb ML; Monia BP
J Clin Invest; 2014 Jan; 124(1):251-61. PubMed ID: 24355919
[TBL] [Abstract][Full Text] [Related]
13. Alpha-1-antitrypsin deficiency: from genoma to liver disease. PiZ mouse as model for the development of liver pathology in human.
Giovannoni I; Callea F; Stefanelli M; Mariani R; Santorelli FM; Francalanci P
Liver Int; 2015 Jan; 35(1):198-206. PubMed ID: 24529185
[TBL] [Abstract][Full Text] [Related]
14. Alpha-1-antitrypsin deficiency: Genetic variations, clinical manifestations and therapeutic interventions.
Hazari YM; Bashir A; Habib M; Bashir S; Habib H; Qasim MA; Shah NN; Haq E; Teckman J; Fazili KM
Mutat Res Rev Mutat Res; 2017 Jul; 773():14-25. PubMed ID: 28927525
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Lipid Profiling Reveals Major Differences between Liver Organoids with Normal Pi*M and Deficient Pi*Z Variants of Alpha-1-antitrypsin.
Pérez-Luz S; Lalchandani J; Matamala N; Barrero MJ; Gil-Martín S; Saz SR; Varona S; Monzón S; Cuesta I; Justo I; Marcacuzco A; Hierro L; Garfia C; Gomez-Mariano G; Janciauskiene S; Martínez-Delgado B
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569847
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of Z Mutant Alpha-1 Antitrypsin In Vivo Using Modified DNA Antisense Oligonucleotides.
Aghajan M; Guo S; Monia BP
Methods Mol Biol; 2017; 1639():127-138. PubMed ID: 28752452
[TBL] [Abstract][Full Text] [Related]
17. In vivo post-transcriptional gene silencing of alpha-1 antitrypsin by adeno-associated virus vectors expressing siRNA.
Cruz PE; Mueller C; Cossette TL; Golant A; Tang Q; Beattie SG; Brantly M; Campbell-Thompson M; Blomenkamp KS; Teckman JH; Flotte TR
Lab Invest; 2007 Sep; 87(9):893-902. PubMed ID: 17592477
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of hepatocyte nuclear factor-4α and defective zonation in livers expressing mutant Z α1-antitrypsin.
Piccolo P; Annunziata P; Soria LR; Attanasio S; Barbato A; Castello R; Carissimo A; Quagliata L; Terracciano LM; Brunetti-Pierri N
Hepatology; 2017 Jul; 66(1):124-135. PubMed ID: 28295475
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy for alpha-1 antitrypsin deficiency.
Flotte TR; Mueller C
Hum Mol Genet; 2011 Apr; 20(R1):R87-92. PubMed ID: 21498872
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Genome Editing With CRISPR/Cas9 in a Humanized Mouse Model Ameliorates α1-antitrypsin Deficiency Phenotype.
Bjursell M; Porritt MJ; Ericson E; Taheri-Ghahfarokhi A; Clausen M; Magnusson L; Admyre T; Nitsch R; Mayr L; Aasehaug L; Seeliger F; Maresca M; Bohlooly-Y M; Wiseman J
EBioMedicine; 2018 Mar; 29():104-111. PubMed ID: 29500128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
